Home/Pipeline/Mezagitamab

Mezagitamab

B-cell malignancies

Phase 1/2Active

Key Facts

Indication

B-cell malignancies

Phase

Phase 1/2

Status

Active

Company

Kyowa Kirin

About Kyowa Kirin

Kyowa Kirin is a leading specialty pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on rare diseases and oncology. The company has built a robust pipeline through internal R&D capabilities and strategic partnerships, with particular expertise in antibody engineering and cell therapy technologies. Kyowa Kirin operates globally with a presence in Japan, Asia-Pacific, North America, and Europe, and is publicly traded on the Tokyo Stock Exchange.

View full company profile

Therapeutic Areas

Rare Diseases Oncology Immunology Nephrology Hematology

Other B-cell malignancies Drugs

Drug	Company	Phase	Status
Pirtobrutinib	Eli Lilly	Phase 3	Active
Velexbru (tirabrutinib)	Ono Pharmaceutical	Phase 3	Active
KT-413	Kymera Therapeutics	Phase 1	Active
TG-1701	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
TG-1801	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
HMPL-760	HUTCHMED	Phase 1	Active
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
UCART20x22	Cellectis	Phase 1/2	Active (in collaboration with Servier)
FT819	Fate Therapeutics	Phase 1	Active
Prulacabtagene leucel (prula-cel, ADI-001)	Adicet Bio	Phase 1	Previously Studied